Boston Scientific Sees Return To Double-Digit Growth In Second Half Of 2000
This article was originally published in The Gray Sheet
Executive Summary
Resumption of Boston Scientific's historic 20%-plus annual sales growth rate will occur the second half of 2000, the company is assuring investors, as key holes in the firm's product pipeline are filled early in the year, including release of advanced coronary stent systems.
You may also be interested in...
Drug/Device Products High On Piper Analyst's List Of Y2K Trends
The clinical efficacy of reducing restenosis by incorporating the anticancer agent paclitaxel with coronary stents is on the cusp of gaining greater clinical backing, Angiotech Pharmaceuticals indicated.
Boston Scientific's Vanguard AAA Graft Effective For High-Risk Patients
Preliminary data from a study of Boston Scientific's Vanguard aortic endograft for treatment of abdominal aortic aneurysms (AAA) show a 97.6% success rate in high-risk patients. The results reinforce a growing consensus among clinicians that the minimally invasive procedure is preferable to standard open surgery for this population.
Drug/Device Products High On Piper Analyst's List Of Y2K Trends
The clinical efficacy of reducing restenosis by incorporating the anticancer agent paclitaxel with coronary stents is on the cusp of gaining greater clinical backing, Angiotech Pharmaceuticals indicated.